scholarly journals Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial

2017 ◽  
Vol 6 (12) ◽  
pp. e242 ◽  
Author(s):  
Shruti Muralidharan ◽  
Viswanathan Mohan ◽  
Ranjit Mohan Anjana ◽  
Sidhant Jena ◽  
Nikhil Tandon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Mobile Health ◽  
Controlled Trial ◽  
Health Technology ◽  
Mobile Health Technology ◽  
Randomized Controlled

scholarly journals Effects of a mobile health diabetes self-management program on HbA1C, self-management and patient satisfaction in adults with uncontrolled type 2 diabetes: a randomized controlled trial

2021 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Chontira Riangkam ◽  
Aurawamon Sriyuktasuth ◽  
Kanaungnit Pongthavornkamol ◽  
Worapan Kusakunniran ◽  
Apiradee Sriwijitkamol
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Patient Satisfaction ◽  
Mobile Health ◽  
Controlled Trial ◽  
Management Program ◽  
Self Management ◽  
Content Type ◽  
Randomized Controlled

PurposeThis study aimed to examine the effects of a three-month mobile health diabetes self-management program (MHDSMP) on glycemic control, diabetes self-management (DSM) behaviors and patient satisfaction in adults with uncontrolled type 2 diabetes (T2DM) in Thailand.Design/methodology/approachThis was a three-arm, parallel-group, randomized controlled trial among 129 adults with uncontrolled T2DM who attended the medical outpatient department in a medical center. The participants were randomly assigned to the three study groups (n = 43 per group), including MHDSMP, telephone follow-up (TF) and usual care (UC). MHDSMP encompassed four components, including DSM engagement, DSM mobile application, motivational text messages and telephone coaching. Outcomes were evaluated at three-month end-of-study by using HbA1C and response to the Summary of Diabetes Self-Care Activities (SDSCA) and the Client Satisfaction Questionnaire (CSQ-8). Data were analyzed by using descriptive statistics and multivariate analysis of covariance (MANCOVA).FindingsThe findings revealed that at the end-of-study, HbA1C decreased from 7.80 to 7.17% (p < 0.001) in MHDSMP group, from 7.72 to 7.65% (p = 0.468) in TF group, and from 7.89 to 7.72% (p = 0.074) in UC group. Significantly higher SDSCA and CSQ-8 scores were also observed in MHDSMP compared to TF and UC groups (F = 12.283, F = 19.541, F = 8.552, p < 0.001, respectively).Originality/valueThis study demonstrated that MHDSMP adjunct with usual care is beneficial for patient outcomes in adults with uncontrolled T2DM in Thailand, compared to TF and UC groups.

scholarly journals A Novel User Utility Score for Diabetes Management Using Digital Health Technology: Results from a Randomized Controlled Trial of a Tailored Mobile Coaching System (Preprint)

2019 ◽  
Author(s):  
Cheol-Young Park ◽  
Min-Kyung Lee ◽  
Da Young Lee ◽  
Hong-Yup Ahn
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Patient Engagement ◽  
Utility Score ◽  
Diabetes Management ◽  
Digital Health ◽  
Controlled Trial ◽  
Health Technology ◽  
Randomized Controlled

BACKGROUND Digital health technology has been developed to support diabetes self-management, but its effectiveness could depend on patient engagement. OBJECTIVE We examined the relationship between novel user utility score (UUS) developed to measure patient engagement and glycemic control among a policyholders with type 2 diabetes. METHODS In 72 participants, we analyzed the association of health outcomes over 12 months with UUS for the first 3 months through a sub-analysis of results from a 12-month randomized controlled trial of a tailored mobile coaching (TMC) system. The UUS was calculated as the sum of scores for four major core components (range 0–8): frequency of self-monitoring blood glucose testing, dietary and exercise records, and message reading rate. RESULTS Participants were divided into two groups: UUS:0–4 (n = 38) and UUS:5–8 (n = 34). Change from baseline in HbA1c was greater with the UUS:5–8 group than the UUS:0–4 group at 3 months (-1.0% vs. -0.37%; P = 0.018), and was sustained through 6 (-0.99 vs. -0.32; P = 0.013) and 12 months (-0.92 vs. -0.33; P = 0.049). Significant differences in changes in HbA1c between the groups were observed over the 12-month period (P for trend < 0.0001). Changes in HbA1c at 3, 6 and 12 months were significantly associated with UUS. CONCLUSIONS UUS as a measure of patient engagement was associated with changes in HbA1c and could be used to predict improved glycemic control in diabetes management using a TMC system in type 2 diabetes. CLINICALTRIAL NCT03033407

1126-P: Randomized Controlled Trial of Ipragliflozin or Sitagliptin Combined with Metformin in Type 2 Diabetes: NISM Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1126-P
Author(s):  
MASARU KITAZAWA ◽  
TAKASHI KATAGIRI ◽  
HIROMI SUZUKI ◽  
SATOSHI MATSUNAGA ◽  
MAYUKO H. YAMADA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document